Attenuation of Beta-Amyloids and Other Risk Factors by a Micronutrient Mixture, Probiotics, Collagen Peptides, Omega 3, and CBD in Alzheimer’s Disease - Abstract
During last decades several endogenous risk factors which participate in the development and progression of Alzheimer’s Disease (AD) have been identified. They include increased oxidative stress, chronic neuroinflammation, mitochondrial dysfunction, autophagic dysfunction, progressive loss of acetylcholine, oxidation of omega-3 fatty acids, increased production of beta-amyloids, hyperphosphorylation of tau protein, loss of collagen, and intestinal dysbiosis. Among these risk factors, beta-amyloids have drawn significant attention from neuroscientists and neurologists. Using beta-amyloids as a target, antibodies have been developed for the treatment of AD. These anti-amyloids antibodies have serious side effects and produce only a short-term benefit in patients with early phase AD. Another risk factor involves gradual decline in the levels of acetylcholine. To address this, drugs which increase the levels of acetylcholine in the cholinergic neurons by inhibiting acetylcholinesterase were developed. The effectiveness of these drugs depends upon the viability of
neurons. Since they do not address the cause of neuronal death, the beneficial effects of these drugs last only for a few months. Neither anti-beta-amyloids
antibodies nor acetylcholinesterase inhibitors have any role in prevention of AD. This review proposes a prevention plan for AD which addresses all endogenous
risk factors including beta-amyloids at the same time. It also suggests that combining drugs with prevention plan together with CBD (cannabidiol) may prolong
the effectiveness of drugs, improve behavior abnormalities associated with AD, and possibly reduce the potential toxicity of drugs.